These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A rational approach to drug use in pregnancy. Zacharias J JOGN Nurs; 1983; 12(3):183-7. PubMed ID: 6553108 [TBL] [Abstract][Full Text] [Related]
5. [Information system provides decision aids for the physician. Drugs in pregnancy and lactation]. Küpper C Fortschr Med; 1998 May; 116(13):36-7. PubMed ID: 9630781 [No Abstract] [Full Text] [Related]
7. [Drug-induced damage in fetuses and young infants]. von Brenndorff AI Monatsschr Kinderheilkd (1902); 1968 Dec; 116(12):626-7. PubMed ID: 5713193 [No Abstract] [Full Text] [Related]
8. Pregnancy exposure registries: academic opportunities and industry responsibility. Wyszynski DF Birth Defects Res A Clin Mol Teratol; 2009 Jan; 85(1):93-101. PubMed ID: 19107953 [TBL] [Abstract][Full Text] [Related]
9. Systematic identification of drugs that cause birth defects--a new opportunity. Mitchell AA N Engl J Med; 2003 Dec; 349(26):2556-9. PubMed ID: 14695418 [No Abstract] [Full Text] [Related]
10. Nordic databases to evaluate medications in pregnancy. Kieler H Therapie; 2014; 69(1):65-9. PubMed ID: 24698190 [TBL] [Abstract][Full Text] [Related]
11. Clinical toxicology of the neonate. Levy M; Koren G Semin Perinatol; 1992 Feb; 16(1):63-75. PubMed ID: 1574726 [No Abstract] [Full Text] [Related]
12. Psychotropic medication in pregnancy: The cost-benefit ratio revised. Alevizopoulos G Psychiatriki; 2015; 26(3):165-8. PubMed ID: 26480220 [No Abstract] [Full Text] [Related]
13. The rationale for a post-marketing surveillance. Westerholm B Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy. Haas DM; Gallauresi B; Shields K; Zeitlin D; Clark SM; Hebert MF; Ren Z; Nallani SC; Meslin EM; Feibus KB; Koren G; Goebel WS; Easterling T; Denne SC; Flockhart DA; Renbarger JL Clin Transl Sci; 2011 Jun; 4(3):204-9. PubMed ID: 21707952 [TBL] [Abstract][Full Text] [Related]
15. Methods for predicting human birth defects. Clayson DB Prog Clin Biol Res; 1985; 163C():197-203. PubMed ID: 3991622 [No Abstract] [Full Text] [Related]
16. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Colvin L; Slack-Smith L; Stanley FJ; Bower C Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1137-50. PubMed ID: 20602344 [TBL] [Abstract][Full Text] [Related]
17. An approach to preventing adverse drug effects during pregnancy. Prescrire Editorial Staff Prescrire Int; 2014 Jan; 23(145):24-6. PubMed ID: 24516911 [No Abstract] [Full Text] [Related]
18. Monitoring and avoiding drug and chemical teratogenicity. Koren G; MacLeod SM CMAJ; 1986 Nov; 135(10):1079-81. PubMed ID: 3094926 [No Abstract] [Full Text] [Related]
19. The effect of prolonged drug usage on fetal development. An epidemiological approach. Roberts CJ Adv Exp Med Biol; 1972; 27():457-65. PubMed ID: 4680140 [No Abstract] [Full Text] [Related]
20. Side-effects and contra-indications. S Afr Med J; 1972 Jun; 46(25):825. PubMed ID: 5076060 [No Abstract] [Full Text] [Related] [Next] [New Search]